New Cancer Treatment Sonesitatug Vedotin Shows Significant Overall Survival Improvement in Advanced Gastric Cancers

Sonesitatug vedotin has demonstrated a statistically significant and clinically meaningful improvement in overall survival for patients with CLDN18.2-positive advanced gastric/gastroesophageal junction (GEJ) cancers in second and later-line treatment. This Phase III trial result suggests the potential for a novel targeted antibody drug conjugate to replace classic chemotherapy and improve patient outcomes.